Sonoma Bio to cement its roots in Seattle with a new waterfront manufacturing and R&D site

A year after Jeff Bluestone’s Sonoma Biotherapeutics netted $265 million in a huge Series B, the biotech is now looking to establish itself in the manufacturing ecosystem of the Pacific Northwest.